Author Archives: admin

DRAM Supply Shortage Expected to Last Until 2028, Micron Target Price Raised by Deutsche Bank by Nearly 70%

As the storm of rising storage prices intensifies, U.S. memory chip giant Micron Technology (NASDAQ:MU) has seen its target price raised once again.

Deutsche Bank significantly raised its target price for Micron Technology while maintaining its “Buy” rating on the stock. The bank’s analysts recently stated that the current memory cycle is “different from past cycles,” which could mean that Micron’s stock still has substantial room for growth.

Deutsche Bank analyst Melissa Weathers expects the supply shortage of dynamic random-access memory (DRAM) to last until at least 2027 or even 2028—especially as the artificial intelligence (AI) boom has led to a surge in demand for high-bandwidth memory (HBM).

HBM is made by stacking DRAM chips and is critical for advanced AI chips, such as those designed by NVIDIA (NASDAQ:NVDA). Micron, along with South Korea’s SK Hynix and Samsung Electronics, is considered one of the “Big Three” in the global HBM market, with the three companies collectively monopolizing more than 97% of the global HBM market share.

In a report released on Tuesday, Weathers noted that compared to traditional DRAM, HBM has approximately three times the “silicon density,” meaning it requires more wafers for chip cutting. She stated that this high density “is causing a supply shock that we believe has not been fully understood.” The supply tightness has enabled companies like Micron to raise prices and sign long-term contracts with customers.

At the same time, Weathers noted that new DRAM wafer plants will take at least two years to come online, and the expansion capacity of existing plants is limited, making it difficult to alleviate the demand pressure. However, she mentioned that as new production capacity gradually comes online next year, the supply constraints may ease.

Weathers believes these trends will create “a more structurally profitable environment” for Micron, raising the stock’s target price by a substantial 67% to $500—more than 30% above the latest closing price.

Deutsche Bank also raised its earnings per share (EPS) forecast for Micron’s fiscal year 2026 to $46.50, with the new target price based on about 11 times this number.

Micron’s stock fell 2.67% on Tuesday, continuing the downward trend from Monday, after reports surfaced that Micron’s competitor Samsung plans to begin mass production of next-generation HBM4 later this month, for use by NVIDIA (NASDAQ:NVDA) in its upcoming Vera Rubin graphics processing unit (GPU).

Over the past year, Micron’s stock has surged by an impressive 300%. Recently, several investment banks, including UBS, Mizuho, and HSBC, have raised their ratings on the stock.

Last month, during Micron’s first-quarter fiscal year 2026 earnings call, the company stated that all of its HBM capacity for 2026 had already been sold out, and it expects the total addressable market (TAM) for HBM to reach $100 billion by 2028 (up from $35 billion in 2025).

OpenAI Races Towards $100 Billion Financing, Altman Claims ChatGPT’s Monthly Growth Rate Returns to Over 10%

Amid growing competitive pressure, OpenAI CEO Sam Altman has informed both employees and investors that the company is maintaining strong momentum in its development.

According to an internal Slack message seen by the media, Altman told OpenAI employees last Friday that the company’s popular AI chatbot, ChatGPT, has “reached a monthly growth rate of over 10% once again.” He also mentioned that OpenAI is preparing to launch an “upgraded chatbot model” this week.

Currently, ChatGPT has surpassed 800 million weekly users, but Google(GOOGL) and Anthropic are steadily eating into its market share. In December last year, OpenAI announced that it had entered a “Code Red” state to make comprehensive improvements to ChatGPT, temporarily putting several projects on hold and concentrating resources on this goal.

In Friday’s internal communication, Altman also mentioned that OpenAI’s programming product Codex had seen a growth of about 50% over the past week.

Codex competes directly with Anthropic’s Claude Code, which has gained a large number of users over the past year.

Last week, OpenAI released a new Codex model—GPT-5.3-Codex—and launched a standalone app for users with Apple computers. According to internal messages, Altman described the growth of Codex as “absolutely crazy.”

“It’s been an amazing week,” Altman wrote.

Investor Messaging
Insiders revealed that as OpenAI approaches completing a financing round that could reach up to $100 billion, Altman and CFO Sarah Friar have been actively pitching the company’s growth story to investors.

In private discussions, the two executives emphasized OpenAI’s advantages in the consumer sector, the expanding enterprise business, and its access to computing resources.

As part of the fundraising discussions, OpenAI presented investors with several charts. According to internal data, Codex is steadily capturing market share from Claude Code.

Insiders said that OpenAI expects the fundraising negotiations to intensify over the next two weeks.

As previously reported, OpenAI’s financing round may occur in two phases. The first phase could involve funding from Microsoft(MSFT), NVIDIA(NVDA), and Amazon(AMZN), with Amazon discussing a potential $50 billion investment in OpenAI. Following this, additional investments from entities like SoftBank could come into play, with SoftBank reportedly considering a $30 billion investment.

However, the specific details of this financing round are still in flux, and the final structure may change.

Ad Testing Launched
On Monday, OpenAI announced the launch of an ad test for ChatGPT in the United States, available to certain free and Go plan subscribers.

OpenAI stated that these ads will be clearly labeled and will appear at the bottom of the chatbot’s responses without affecting the content of the answers.

The digital advertising market has long been dominated by Google and Meta, with Amazon gradually becoming an important player in recent years.

It is reported that OpenAI expects that, in the long term, ad revenue will account for less than half of its overall earnings.

AI Arms Race Sparks Semiconductor Surge, NVIDIA Rises Nearly 8%, Achieving the Strongest Rally in 10 Months

The AI “arms race” has triggered a semiconductor frenzy, with NVIDIA (NASDAQ:NVDA) stock surging nearly 8%, marking its strongest rise in nearly 10 months. Earlier, six of the seven tech giants had already reported their earnings, with the most noteworthy being that Google (NASDAQ:GOOGL), Microsoft (NASDAQ:MSFT), Amazon (NASDAQ:AMZN), and Meta Platforms (NASDAQ:META) will collectively spend approximately $650 billion on capital expenditures in 2026.

Last week, Meta announced its capital expenditures would rise to as much as $135 billion for the year, representing an 87% increase. Meanwhile, Microsoft reported a 66% year-on-year growth in its capital expenditures for Q2, and analysts predict its fiscal year capital spending through June will approach $105 billion.

Jensen Huang, CEO of NVIDIA, specifically praised OpenAI and Anthropic, two leading AI labs, stating that both are “making a lot of money.” NVIDIA invested $10 billion in Anthropic last year, and Huang earlier this week indicated plans to significantly invest in OpenAI’s next funding round. He mentioned, “If they can have twice the computing power, their revenue will increase fourfold.”

Earlier, Taiwan Semiconductor Manufacturing Company (NYSE:TSM), the world’s leading semiconductor foundry, set new performance records and announced plans to significantly increase its capital expenditures to $52-56 billion in 2026, far exceeding market expectations. This is aimed at accelerating the expansion of advanced manufacturing capacity to address the ongoing global shortage of AI chips.

CPO Industry Accelerates, Lumentum Surges Over 9%

NVIDIA, in a recent webinar, announced that three partners—CoreWeave (NYSE:CRWV), Lambda, and TACC—will deploy the IB CPO system in the first half of 2026, and Ethernet CPO products are expected to start shipping in the second half of 2026. The company believes that the CPO industry is advancing more quickly than expected, with the technology first landing in scale-out scenarios and expanding into larger market spaces. As a next-generation optical interconnect solution, the commercial value of CPO continues to become clearer, and its market potential is expanding.

Lumentum (NASDAQ:LITE) CEO Michael Hurlston stated in a recent earnings call that the company’s ongoing growth is primarily driven by cloud optical modules, OCS, and CPO. The development of the OCS business has exceeded expectations, with the first $10 million quarterly revenue target, initially set for Q3, being reached ahead of schedule. Demand for OCS from three core customers has surged, and Hurlston revealed that there is a backlog of over $400 million in OCS orders, most of which are planned to be delivered in the second half of 2026. Orders and revenue are expected to continue growing as they enter 2027.

Roivant Sciences Surges Over 22% After Promising Skin Disease Results

Roivant Sciences (NASDAQ:ROIV) saw its stock rise more than 22% after its subsidiary Priovant Therapeutics reported positive results from the phase 2 trial of its experimental drug brepocitinib. The drug showed improvements in the activity of skin nodular disease at higher doses. Another subsidiary, Pulmovant, also announced the completion of phase 2 trial enrollment involving around 120 patients for its experimental drug mosliciguat, aimed at treating pulmonary arterial hypertension associated with lung disease.

Priovant reported that patients taking a 45 mg dose showed a 22.3-point improvement on a key skin scoring system at week 16, while the placebo group showed only a 0.7-point improvement. The company noted that all patients in the 45 mg group showed significant improvement, with 62% achieving near-complete skin clearance, and 69% achieving complete or nearly complete clearance, while none of the placebo group patients achieved similar results.

Priovant plans to launch phase 3 trials in 2026, following consultations with the U.S. Food and Drug Administration (FDA).